Neural Mechanisms With CES in Depression

Sponsor
Electromedical Products International, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04587531
Collaborator
(none)
60
1
2
29.9
2

Study Details

Study Description

Brief Summary

This study will examine the effect of cranial electrotherapy stimulation (CES) treatment on adults with depression. Scalp based electroencephalogram (EEG) will be utilized to record the brain activity of participants whilst they perform computer based tasks. The aim is to understand if there would be changes in the neural signals following CES.

Condition or Disease Intervention/Treatment Phase
  • Device: Cranial Electrotherapy Stimulation
N/A

Detailed Description

Patients meeting the inclusion and exclusion criteria and volunteer to participate will be randomly assigned to "Active CES Therapy" and "Sham CES Therapy" groups. Before start of the treatment (active or sham), their medication details or any other form of treatment they are on will be noted down. These patients will be assessed on self-rated Beck Depression Inventory and clinician rated Hamilton Depression Rating Scale. They will be also assessed on neuropsychological functions of attention, executive functions, memory, information processing and emotional processing evaluation using Emotional Test Battery. In addition, 25 patients from each group will undergo EEG recording whilst they perform computer based tasks. These assessments will take place at 4 time points (Pre-treatment, 1 month after treatment, at 3 months, and at 6 months after treatment).

The study will use scalp based electroencephalogram (EEG) to record the brain activity of participants whilst they perform computer based tasks. The aim is to understand if there would be changes in the neural signals following cranial electrotherapy stimulation. Investigators propose to use EEG to investigate if CES therapy will modulate brain responses in a way that leads to better information processing as a mechanism to improve depression. Furthermore, researchers will also investigate changes in EEG based brain connectivity patterns following CES therapy. Therefore, as a mechanism of action for CES therapy could be changes in the functional brain connectivity for efficient information processing. EEG investigation will be helpful to understand this connectivity based mechanism following CES.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A 6-week, randomized, double-blind, placebo controlled evaluation of efficacy and tolerability of cranial electrotherapy stimulation (CES) for the treatment of adults with depression. EEG readings will evaluate changes in neural signals following CES treatment.A 6-week, randomized, double-blind, placebo controlled evaluation of efficacy and tolerability of cranial electrotherapy stimulation (CES) for the treatment of adults with depression. EEG readings will evaluate changes in neural signals following CES treatment.
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
Treatment device will deliver subsensory treatment while the sham device will deliver no treatment.
Primary Purpose:
Treatment
Official Title:
Understanding Neural Mechanisms Associated With Cranial Electrotherapy Stimulation in Depression
Actual Study Start Date :
Jul 5, 2021
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Active CES Therapy

Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.

Device: Cranial Electrotherapy Stimulation
Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
Other Names:
  • Alpha-Stim
  • Sham Comparator: Sham CES Therapy

    Group receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.

    Device: Cranial Electrotherapy Stimulation
    Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
    Other Names:
  • Alpha-Stim
  • Outcome Measures

    Primary Outcome Measures

    1. Change in Electroencephalogram (EEG) pre-and post-treatment [Pre-treatment; 1 month, 3 months, and 6 months post-treatment]

      Scalp based EEG to measure changes in neural signals

    2. Change in Beck Depression Inventory score [Week 1 and Week 6]

      Self-report standardized measure of depression with scores ranging from 0-63 with higher scores indicating more severe depression.

    3. Change in Hamilton Depression Rating Scale [Week 1 and Week 6]

      Clinician rated standardized measure of depression with scores ranging from 0-50, with higher scores indicating more severe depression.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Male or female subjects, 18 to 65 years of age.

    • Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document.

    • Subjects must fulfil ICD-10 criteria for Depressive Episode or Recurrent Depressive Disorders based on clinical assessment and confirmed by short a structured diagnostic interview, MINI.

    • Subjects must have an initial score of at least 14 on the BDI at screen and at baseline of study.

    • Current depressive episode of at least 4 weeks duration.

    Exclusion Criteria:
    • Current or past diagnosis of any other major mental disorders (e.g., schizophrenia, bipolar affective disorders)

    • Depression with psychotic symptoms

    • Dysthymia

    • Depression of organic origin

    • Substance misuse/ dependence

    • Subjects with one or more seizures without a clear and resolved etiology.

    • Female subjects who are pregnant.

    • Subjects who, in the investigator's judgment, pose a current serious suicidal or homicidal risk

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Oxford Brooke University Oxford United Kingdom

    Sponsors and Collaborators

    • Electromedical Products International, Inc.

    Investigators

    • Principal Investigator: Sanjay Kumar, PhD, Oxford Brooke University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Electromedical Products International, Inc.
    ClinicalTrials.gov Identifier:
    NCT04587531
    Other Study ID Numbers:
    • UK-MDDEEG
    First Posted:
    Oct 14, 2020
    Last Update Posted:
    Jul 21, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Electromedical Products International, Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 21, 2021